(Q42612040)

English

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

scientific article published on 7 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients (English)

1 reference

Europe PubMed Central

3 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tenofovir/emtricitabine

1 reference

based on heuristic

inferred from title

Christine Katlama

10

object named as

C Katlama

1 reference

Europe PubMed Central

3 November 2017

16

object named as

P Reiss

1 reference

Europe PubMed Central

3 November 2017

author name string

S M E Vrouenraets

1

1 reference

Europe PubMed Central

3 November 2017

F W N M Wit

2

1 reference

Europe PubMed Central

3 November 2017

E Fernandez Garcia

3

1 reference

Europe PubMed Central

3 November 2017

G J Moyle

4

1 reference

Europe PubMed Central

3 November 2017

A G Jackson

5

1 reference

Europe PubMed Central

3 November 2017

C Allavena

6

1 reference

Europe PubMed Central

3 November 2017

F Raffi

7

1 reference

Europe PubMed Central

3 November 2017

D T Jayaweera

8

1 reference

Europe PubMed Central

3 November 2017

S Mauss

9

1 reference

Europe PubMed Central

3 November 2017

M Fisher

11

1 reference

Europe PubMed Central

3 November 2017

L Slama

12

1 reference

Europe PubMed Central

3 November 2017

W D Hardy

13

1 reference

Europe PubMed Central

3 November 2017

E Dejesus

14

1 reference

Europe PubMed Central

3 November 2017

A van Eeden

15

1 reference

Europe PubMed Central

3 November 2017

BASIC Study Group

17

1 reference

Europe PubMed Central

3 November 2017

publication date

7 August 2011

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

12

1 reference

Europe PubMed Central

3 November 2017

10

1 reference

Europe PubMed Central

3 November 2017

620-631

1 reference

Europe PubMed Central

3 November 2017

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

HIV protease inhibitors activate the adipocyte renin angiotensin system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2011.00941.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2011.00941.X

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42612040&oldid=1962826736"